Ning Ren

ORCID: 0009-0001-9881-5659
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HER2/EGFR in Cancer Research
  • RNA modifications and cancer
  • Cancer Immunotherapy and Biomarkers
  • Endometriosis Research and Treatment
  • Advanced Breast Cancer Therapies
  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • CAR-T cell therapy research
  • Lung Cancer Treatments and Mutations
  • Reproductive System and Pregnancy
  • Colorectal Cancer Treatments and Studies
  • Ferroptosis and cancer prognosis
  • Phytochemistry and Bioactive Compounds
  • Diet and metabolism studies
  • RNA Research and Splicing
  • Ovarian function and disorders
  • Integrated Circuits and Semiconductor Failure Analysis
  • Cancer, Lipids, and Metabolism
  • Pregnancy and preeclampsia studies
  • Endometrial and Cervical Cancer Treatments
  • Traditional Chinese Medicine Analysis
  • Cancer-related gene regulation
  • Protein Tyrosine Phosphatases
  • Inflammasome and immune disorders
  • BRCA gene mutations in cancer

Fudan University
2023-2025

Minhang District Central Hospital
2023-2025

Zhejiang Chinese Medical University
2021-2024

Hangzhou Hospital of Traditional Chinese Medicine
2022-2024

Hangzhou First People's Hospital
2024

CM Hospital
2023

Zhongshan Hospital
2023

Abstract Liver cancer is one of the most common cancers in world and a primary cause cancer-related death. In recent years, despite great development diagnostic methods targeted therapies for liver cancer, incidence mortality are still on rise. As universal post-transcriptional modification, N6-methyladenosine (m6A) modification accomplishes dynamic reversible m6A process, which executed by three types regulators, methyltransferases (called writers), demethylases erasers) m6A-binding...

10.1186/s12935-023-03197-x article EN cc-by Cancer Cell International 2024-01-02

Pathological images of hepatocellular carcinoma (HCC) contain abundant tumor information that can be used to stratify patients. However, the links between histology and treatment response have not been fully unveiled. We trained evaluated a model by predicting prognosis 287 non-treated HCC patients postoperatively, further explored model's predictive ability in 79 sorafenib-treated Based on prognostic relevant pathological signatures (PPS) extracted from CNN-SASM, which was denoised...

10.1186/s12916-025-03977-4 article EN cc-by-nc-nd BMC Medicine 2025-03-18

The ketogenic diet (KD) is recommended to improve polycystic ovary syndrome (PCOS); however, its mechanisms of action are unclear. We aimed study the effects and KD on gut microbiome metabolites in PCOS rats determine whether sex hormone regulatory related modulations microbiota metabolites.PCOS was induced with a high-fat letrozole rats. A fed for 8 wk, serum samples were collected biochemical analysis, rats' fecal subjected 16S ribosomal RNA sequencing metabolomic analysis.Feeding wk...

10.1016/j.nut.2023.112127 article EN cc-by-nc-nd Nutrition 2023-06-08

Prostate cancer (PCa) affects males of all racial and ethnic groups, leads to higher rates mortality in those belonging a lower socioeconomic status due the late detection disease. PCa middle‑aged between ages 45 60 years, is highest cause cancer‑associated Western countries. As most abundant common mRNA modification eukaryotes, N

10.3892/or.2024.8747 article EN cc-by-nc-nd Oncology Reports 2024-05-13

Breast cancer (BC) is one of the most common malignant tumors in women. In addition, human epidermal growth factor receptor 2-positive (HER2+) BC overexpressed 25% patients, resulting predicament poor prognosis. Although first- and second-line treatments have been established, optimum third-line treatment still mired controversies for HER2+ metastatic (mBC). Therefore, this study analyzes cost-effectiveness neratinib plus capecitabine (N+C) lapatinib (L+C) over a 5-year time horizon from...

10.3389/fonc.2023.1221969 article EN cc-by Frontiers in Oncology 2023-08-09

<title>Abstract</title> <bold>Background: </bold>Breast cancer is one of the most common malignant tumors in women. Human epidermal growth factor receptor 2 (HER2) -positive advanced breast has poor prognosis and short survival period. EMILIA was a global phase III study to evaluate efficacy Trastuzumab emtansine (T-DM1) Capecitabine plus lapatinib. However, cost-effectiveness T-DM1 still unclear. Therefore, objective this lapatinib treating HER2-positive within 5 years from perspective...

10.21203/rs.3.rs-3977552/v1 preprint EN cc-by Research Square (Research Square) 2024-02-27

To investigate the effect of Chinese medicine He's Yangchao recipe on premature ovarian insufficiency (POI) and its relationship with mitochondrial function granulose cells in an animal model.

10.3724/zdxbyxb-2023-0521 article EN PubMed 2024-03-29

<title>Abstract</title> <italic>Objective and Design</italic>: Asthma is becoming an inflammatory disease of the airways involving a variety cells cell components.In this study,we attempted to investigate protective effect underlying mechanism potential plant derived natural compound,1,8-cineol.Transforming growth factor-beta TGF-β1-induced epithelial-mesenchymal transition (EMT) in bronchial epithelial contributes airway wall remodeling asthma. Epithelial-mesenchymal represents important...

10.21203/rs.3.rs-4880907/v1 preprint EN Research Square (Research Square) 2024-09-09

Abstract Objective: Breast cancer is one of the tumors with highest prevalence rate among women in world, and its BRCA1/2 gene a common mutation site. Talazoparib, as targeted PARP inhibitor, can effectively control occurrence development breast mutation, play therapeutic role. Based on phase III EMBRACE trial (NCT01945775 clinical trial), this paper aims to use Talazoparib's scheme treat HER2-negative advanced obtain economic cost-effectiveness Talazoparib. This article conducts...

10.21203/rs.3.rs-3475563/v1 preprint EN cc-by Research Square (Research Square) 2023-10-28
Coming Soon ...